Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 17/20 | 0.40 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13117692 | 1.00 | CD274 (0.40) | CD274PDCD1KDM4EFFAR1 | |
| SCHEMBL13117695 | 0.90 | FFAR1 (0.41) | CD274PDCD1KDM4EFFAR1 | |
| SCHEMBL13117706 | 0.90 | FFAR1 (0.41) | CD274PDCD1KDM4EFFAR1 | |
| SCHEMBL12578360 | 0.90 | FFAR1 (0.41) | CD274FFAR1 | |
| SCHEMBL12578361 | 0.90 | FFAR1 (0.41) | CD274FFAR1 | |
| SCHEMBL13213362 | 0.89 | CD274 (0.38) | CD274PDCD1KDM4EFFAR1 | |
| SCHEMBL13117752 | 0.85 | FFAR1 (0.42) | CD274PDCD1KDM4EFFAR1 | |
| SCHEMBL12578397 | 0.85 | CD274 (0.41) | CD274PDCD1KDM4EFFAR1 | |
| SCHEMBL12578278 | 0.82 | CD274 (0.44) | CD274PDCD1KDM4E | |
| SCHEMBL12578387 | 0.80 | FFAR1 (0.46) | CD274FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267775-A1 | OXADIAZOLIDINEDIONE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-10-21 | — | — | US | disclosed |
| US-20100267775-A1 | OXADIAZOLIDINEDIONE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-10-21 | — | — | US | disclosed |
| EP-2216330-A1 | OXADIAZOLIDINEDIONE COMPOUND | Astellas Pharma Inc. (JP) | 2010-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267775-A1 | OXADIAZOLIDINEDIONE COMPOUND | GPR119, GLP1R, GPR4 | CD274 1333/4885PDCD1 1246/4885KDM4E 2459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.